Search - tctmd.com

Displaying 21 - 39 of 39

Sort: Relevancy | Date

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Daily News

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

Todd Neale

June 22, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

February 25, 2013

CME

Advertisement

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

FDA Approves Icosapent Ethyl for Reducing CVD Events

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Recurrent Events Common Among Young Patients With CAD

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

No Need for Niacin? Meta-analysis Argues the End Is Nigh

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Top News in Clinical Cardiology: 2018

Top News in Prevention: 2018

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content